Avalo Therapeutics Inc. (AVTX) Fundamentals

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.
SHARE INFORMATION
Market CapUS$ 33,849,540
Shares Outstanding112,794,203
Float63,593,833
Percent Float56.38%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0.00
Latest Fiscal RevenueUS$ 5,397,000
Latest Fiscal EPSUS$ -0.83
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)US$ 0.00
Dividend (5 Years)US$ 0.00
Ex Dividend Date-
Dividend RateUS$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions161
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months4,419,731
Institutional Holdings Percent86.2%
Institutional Sold Previous 3 Months2,415,365
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months4,456,367
Insider Holdings Percent2.4
Insider Sold Previous 3 Months-
Insider Shares Owned2,724,689
TRADING INFO
52 Week HighUS$ 3.70
52 Week LowUS$ 0.20
52 Week High ChangeUS$ -88.41
21 Day Moving AverageUS$ 0.336
21 Day Extended Moving AverageUS$ 0.360706
50 Day Moving AverageUS$ 0.5276
50 Day Extended Moving AverageUS$ 0.512099
200 Day Moving AverageUS$ 1.5161
200 Day Extended Moving AverageUS$ 1.326
10 Day Average Volume421,554
20 Day Average Volume581,284
30 Day Average Volume523,746
50 Day Average Volume442,481
Alpha0.003655
Beta2.1055
Standard Deviation0.242500
R20.168918
7 Day Price ChangeUS$ -0.0259
7 Day Percent Change-7.94%
21 Day Price ChangeUS$ -0.0938
21 Day Percent Change-23.81%
30 Day Price ChangeUS$ -0.29
30 Day Percent Change-49.14%
Month to Date Price ChangeUS$ -0.1107
Month to Date Percent Change-26.95%
Quarter to Date Price ChangeUS$ -0.4246
Quarter to Date Percent Change-58.59%
180 Day Price ChangeUS$ -1.87
180 Day Percent Change-86.17%
200 Day Price ChangeUS$ -2.07
200 Day Percent Change-87.34%
Year to Date Price ChangeUS$ -1.40
Year to Date Percent Change-82.35%

Avalo Therapeutics Inc. (AVTX) Key Ratios

PROFITABILITY
EBIT Margin-1,187.4%
EBITDA Margin-1,166.5%
Pre-Tax Profit Margin-2,030.3%
Profit Margin Count0.0%
Gross Margin65.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
RevenueUS$ 6,097,000
Revenue Per ShareUS$ 0.0541
Revenue (3 Years)US$ -25.78
Revenue (5 Years)US$ -4.05
FINANCIAL STRENGTH
Price to Tangible Book-4.50
Total Debt To Equity5.30
Int Coverage-79.70
Current Ratio2.40
Leverage Ratio3.30
Quick Ratio2.30
Long Term Debt To Capital0.84
VALUATION MEASURES
PE Ratio-0.50
Enterprise ValueUS$ 31,420,380
Price to Sales5.5518
Price to Free Cash-0.50
PE High Last 5 Years-2.30
Price To Book5.70
Price To Cash Flow7.40
PE Low Last 5 Years-54.50
Price to Tangible Book-4.50
MANAGEMENT EFFECTIVENESS
Receivables Turnover1.90
Invoice Turnover161.80
Assets Turnover0.10
Return Assets-122.00
Return on Equity-394.41
Return on Capital-139.11

Avalo Therapeutics Inc. (AVTX) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOGarry A. Neil
Emplyoees44
Last AuditUE
CIK0001534120
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address540 Gaither Road
Suite 400
Rockville, MD 20850
Websitehttps://www.avalotx.com
Facsimile-
Telephone+1 410 522-8707
Emailjharrell@cerecor.com
Your Recent History
NASDAQ
AVTX
Avalo Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20220526 14:21:06